What is Jaguar Health Inc's earnings per share (EPS)?

Jaguar Health Inc (JAGX) reported diluted earnings per share of $-0.13 for fiscal year 2024. This represents a 95.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Jaguar Health Inc Financials

JAGX

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Jaguar Health Inc (JAGX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 17/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Jaguar Health Inc has an operating margin of -263.8%, meaning the company retains $-264 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -351.3% the prior year.

Growth

Jaguar Health Inc's revenue surged 19.8% year-over-year to $11.7M, reflecting rapid business expansion. This strong growth earns a score of 66/100.

Leverage

Jaguar Health Inc has elevated debt relative to equity (D/E of 6.84), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

Jaguar Health Inc's current ratio of 1.63 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 28/100, which could limit financial flexibility.

Cash Flow

While Jaguar Health Inc generated -$29.4M in operating cash flow, capex of $16K consumed most of it, leaving -$29.4M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Jaguar Health Inc generates a -0.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 10/100. This is up from -0.9% the prior year.

Piotroski F-Score Weak

3/9

Jaguar Health Inc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

748.64x

For every $1 of reported earnings, Jaguar Health Inc generates $748.64 in operating cash flow (-$29.4M OCF vs -$39K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-133.5x

Jaguar Health Inc earns $-133.5 in operating income for every $1 of interest expense (-$30.8M vs $231K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$11.7M

YoY+19.8%

5Y CAGR+15.1%

Jaguar Health Inc generated $11.7M in revenue in fiscal year 2024. This represents an increase of 19.8% from the prior year.

EBITDA

-$28.9M

YoY+10.4%

Jaguar Health Inc's EBITDA was -$28.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 10.4% from the prior year.

Net Income

-$39K

YoY+6.3%

Jaguar Health Inc reported -$39K in net income in fiscal year 2024. This represents an increase of 6.3% from the prior year.

EPS (Diluted)

$-0.13

YoY+95.1%

Jaguar Health Inc earned $-0.13 per diluted share (EPS) in fiscal year 2024. This represents an increase of 95.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$29.4M

Jaguar Health Inc generated -$29.4M in free cash flow in fiscal year 2024, representing cash available after capex.

Cash & Debt

$8.0M

YoY+23.7%

5Y CAGR+18.0%

10Y CAGR+25.2%

Jaguar Health Inc held $8.0M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

83.3%

YoY+4.1pp

5Y CAGR+49.4pp

Jaguar Health Inc's gross margin was 83.3% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 4.1 percentage points from the prior year.

Operating Margin

-263.8%

YoY+87.6pp

5Y CAGR+237.5pp

Jaguar Health Inc's operating margin was -263.8% in fiscal year 2024, reflecting core business profitability. This is up 87.6 percentage points from the prior year.

Net Margin

-0.3%

YoY+0.1pp

5Y CAGR+667.0pp

Jaguar Health Inc's net profit margin was -0.3% in fiscal year 2024, showing the share of revenue converted to profit. This is up 0.1 percentage points from the prior year.

Return on Equity

-0.6%

YoY+0.3pp

5Y CAGR+360.5pp

Jaguar Health Inc's ROE was -0.6% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 0.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$16.5M

YoY-11.0%

5Y CAGR+23.2%

10Y CAGR+14.6%

Jaguar Health Inc invested $16.5M in research and development in fiscal year 2024. This represents a decrease of 11.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$16K

10Y CAGR-11.6%

Jaguar Health Inc invested $16K in capex in fiscal year 2024, funding long-term assets and infrastructure.

JAGX Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$11.7M+19.8%	$9.8M-18.4%	$12.0M+175.8%	$4.3M-53.8%	$9.4M+62.5%	$5.8M
Cost of Revenue	$2.0M-4.0%	$2.0M+0.9%	$2.0M-13.5%	$2.3M-28.9%	$3.3M-14.0%	$3.8M
Gross Profit	$9.7M+26.0%	$7.7M-22.3%	$9.9M+396.4%	$2.0M-67.2%	$6.1M+211.6%	$2.0M
R&D Expenses	$16.5M-11.0%	$18.6M+5.4%	$17.6M+17.0%	$15.1M+135.1%	$6.4M+10.2%	$5.8M
SG&A Expenses	$16.3M-1.5%	$16.6M-7.2%	$17.9M+4.5%	$17.1M+18.9%	$14.4M+6.6%	$13.5M
Operating Income	-$30.8M+10.1%	-$34.3M+0.4%	-$34.4M+15.5%	-$40.7M-52.8%	-$26.6M+7.9%	-$28.9M
Interest Expense	$231K-96.4%	$6.4M-49.8%	$12.7M+51.1%	$8.4M+201.6%	$2.8M-51.3%	$5.7M
Income Tax	$0	$0	$0	$0	$0-100.0%	$10K
Net Income	-$39K+6.3%	-$42K+13.4%	-$48K+8.0%	-$53K+99.8%	-$33.8M+12.3%	-$38.5M
EPS (Diluted)	$-0.13+95.1%	$-2.68-7298.3%	$-0.04+59.0%	$-0.09+97.1%	$-3.00	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	$3.1M+3.5%	$3.0M+34.6%	$2.2M-36.9%	$3.5M+12.9%	$3.1M+14.2%	$2.7M+15.7%	$2.4M	N/A
Cost of Revenue	$532K+448.5%	$97K-81.2%	$515K-7.5%	$557K+3.0%	$541K+26.7%	$427K-0.7%	$430K	N/A
Gross Profit	$2.6M-11.5%	$2.9M+69.6%	$1.7M-42.4%	$3.0M+15.0%	$2.6M+11.9%	$2.3M+19.4%	$1.9M	N/A
R&D Expenses	$3.7M+12.0%	$3.3M-12.5%	$3.7M-17.7%	$4.5M+12.1%	$4.0M+10.7%	$3.7M-15.3%	$4.3M	N/A
SG&A Expenses	$4.1M-12.5%	$4.7M-3.5%	$4.9M+26.9%	$3.9M+2.2%	$3.8M-12.5%	$4.3M-1.5%	$4.4M	N/A
Operating Income	-$7.2M+9.6%	-$8.0M+15.0%	-$9.4M-15.5%	-$8.2M-12.3%	-$7.3M-0.9%	-$7.2M+12.4%	-$8.2M	N/A
Interest Expense	$6K+140.0%	-$15K+73.2%	-$56K+49.1%	-$110K+32.1%	-$162K-50.0%	-$108K-117.7%	$611K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	$0	$0	N/A
Net Income	-$9.5M+8.7%	-$10.4M+0.5%	-$10.5M-136.7%	$28.5M+389.6%	-$9.9M-3.8%	-$9.5M-2.9%	-$9.2M	N/A
EPS (Diluted)	$-6.28+38.8%	$-10.26+38.6%	$-16.70	N/A	$-26.29-888.3%	$-2.66+96.9%	$-87.12	N/A

JAGX Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$53.4M+5.2%	$50.8M+7.0%	$47.5M-10.9%	$53.3M+24.3%	$42.8M+17.7%	$36.4M
Current Assets	$32.2M+15.1%	$28.0M+25.3%	$22.3M-21.5%	$28.4M+59.8%	$17.8M+86.9%	$9.5M
Cash & Equivalents	$8.0M+23.7%	$6.5M+18.3%	$5.5M-67.9%	$17.1M+110.8%	$8.1M+131.5%	$3.5M
Inventory	$10.3M+12.6%	$9.2M+30.8%	$7.0M+43.3%	$4.9M+76.1%	$2.8M+30.7%	$2.1M
Accounts Receivable	$1.5M-22.4%	$2.0M+4.7%	$1.9M+9.9%	$1.7M-18.5%	$2.1M+24.0%	$1.7M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$44.4M-3.1%	$45.9M-6.0%	$48.8M+17.9%	$41.4M+61.5%	$25.6M-0.4%	$25.7M
Current Liabilities	$19.7M+40.9%	$14.0M-53.9%	$30.3M+96.1%	$15.5M+17.0%	$13.2M-14.1%	$15.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$6.5M+32.6%	$4.9M+460.3%	-$1.4M-111.5%	$11.9M-31.1%	$17.2M+61.2%	$10.7M
Retained Earnings	-$346.5M-12.4%	-$308.2M-15.5%	-$266.9M-21.6%	-$219.5M-31.5%	-$166.9M-25.4%	-$133.1M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$49.5M+2.5%	$48.3M-6.2%	$51.5M-3.7%	$53.4M-8.6%	$58.5M-4.9%	$61.5M+11.0%	$55.4M+9.1%	$50.8M
Current Assets	$29.4M+5.4%	$27.9M-8.3%	$30.4M-5.5%	$32.2M-12.1%	$36.6M-8.6%	$40.1M+19.0%	$33.7M+20.6%	$28.0M
Cash & Equivalents	$3.5M+59.8%	$2.2M-61.2%	$5.7M-28.9%	$8.0M-39.7%	$13.3M-17.3%	$16.0M+37.5%	$11.7M+80.4%	$6.5M
Inventory	$10.6M-0.8%	$10.7M+1.6%	$10.6M+2.0%	$10.3M+6.9%	$9.7M+1.2%	$9.6M+5.9%	$9.0M-1.8%	$9.2M
Accounts Receivable	$1.4M+22.5%	$1.2M-4.1%	$1.2M-19.9%	$1.5M+22.3%	$1.2M-3.8%	$1.3M-14.1%	$1.5M-23.1%	$2.0M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$45.1M+9.0%	$41.4M-14.0%	$48.1M+8.3%	$44.4M+3.6%	$42.9M+1.1%	$42.4M+3.2%	$41.1M-10.4%	$45.9M
Current Liabilities	$36.1M+23.6%	$29.2M+3.6%	$28.2M+43.2%	$19.7M-0.9%	$19.9M+3.9%	$19.1M+7.4%	$17.8M+27.4%	$14.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.4M-36.6%	$6.9M+728.9%	$830K-87.2%	$6.5M-50.4%	$13.1M-21.0%	$16.6M+40.3%	$11.8M+141.4%	$4.9M
Retained Earnings	-$376.9M-2.6%	-$367.4M-2.9%	-$356.9M-3.0%	-$346.5M-2.9%	-$336.6M-3.0%	-$326.7M-3.0%	-$317.2M-2.9%	-$308.2M

JAGX Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$29.4M+11.6%	-$33.2M-0.4%	-$33.1M+5.3%	-$35.0M-128.9%	-$15.3M+25.3%	-$20.5M
Capital Expenditures	$16K	N/A	$77K+1183.3%	$6K-14.3%	$7K	N/A
Free Cash Flow	-$29.4M	N/A	-$33.2M+5.1%	-$35.0M-128.8%	-$15.3M	N/A
Investing Cash Flow	-$231K	N/A	-$1.7M-27816.7%	-$6K+14.3%	-$7K	N/A
Financing Cash Flow	$31.2M-8.8%	$34.2M+47.7%	$23.2M-47.2%	$43.9M+125.4%	$19.5M-10.5%	$21.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$4.7M+24.3%	-$6.2M+15.3%	-$7.3M+6.5%	-$7.8M-23.4%	-$6.3M+22.4%	-$8.2M-15.9%	-$7.0M+5.4%	-$7.5M
Capital Expenditures	N/A	N/A	N/A	$0	$0	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	-$7.8M-23.4%	-$6.3M	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	-$215K	$0	N/A	N/A	N/A
Financing Cash Flow	$6.3M+135.7%	$2.7M-46.5%	$5.0M+75.5%	$2.8M-19.8%	$3.5M-71.9%	$12.6M+2.5%	$12.3M+15.2%	$10.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

JAGX Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	83.3%+4.1pp	79.1%-4.0pp	83.1%+36.9pp	46.2%-18.9pp	65.0%+31.1pp	33.9%
Operating Margin	-263.8%+87.6pp	-351.3%-63.5pp	-287.8%+651.2pp	-939.0%-655.1pp	-283.9%+217.3pp	-501.3%
Net Margin	-0.3%+0.1pp	-0.4%-0.0pp	-0.4%+0.8pp	-1.2%+359.0pp	-360.3%+307.1pp	-667.3%
Return on Equity	-0.6%+0.3pp	-0.9%	N/A	-0.4%+196.1pp	-196.5%+164.5pp	-361.1%
Return on Assets	-0.1%+0.0pp	-0.1%+0.0pp	-0.1%0.0pp	-0.1%+78.8pp	-78.9%+26.9pp	-105.8%
Current Ratio	1.63-0.4	2.00+1.3	0.74-1.1	1.84+0.5	1.35+0.7	0.62
Debt-to-Equity	6.84-2.5	9.37+45.3	-35.91-39.4	3.49+2.0	1.49-0.9	2.41
FCF Margin	-251.5%	N/A	-277.5%+529.3pp	-806.8%-644.0pp	-162.9%	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	82.7%-14.0pp	96.7%+20.0pp	76.7%-7.4pp	84.1%+1.5pp	82.6%-1.7pp	84.3%+2.6pp	81.7%	N/A
Operating Margin	-234.8%+34.0pp	-268.8%+156.7pp	-425.5%-193.1pp	-232.5%+1.2pp	-233.7%+30.8pp	-264.5%+84.9pp	-349.4%	N/A
Net Margin	-308.2%+41.1pp	-349.4%+123.3pp	-472.6%-1285.8pp	813.1%+1130.2pp	-317.1%+31.8pp	-348.8%+43.6pp	-392.4%	N/A
Return on Equity	-218.0%-66.7pp	-151.3%+1109.5pp	-1260.7%-1700.1pp	439.4%+514.6pp	-75.2%-18.0pp	-57.3%+20.8pp	-78.1%	N/A
Return on Assets	-19.2%+2.4pp	-21.6%-1.2pp	-20.3%-73.7pp	53.4%+70.3pp	-16.9%-1.4pp	-15.4%+1.2pp	-16.7%	N/A
Current Ratio	0.81-0.1	0.95-0.1	1.08-0.6	1.63-0.2	1.84-0.3	2.10+0.2	1.89-0.1	2.00
Debt-to-Equity	10.35+4.3	6.02-52.0	58.01+51.2	6.84+3.6	3.27+0.7	2.56-0.9	3.48-5.9	9.37
FCF Margin	N/A	N/A	N/A	-223.0%-19.0pp	-204.0%	N/A	N/A	N/A

Similar Companies

Quoin Pharmaceuticals Ltd QNRX

$12.7M

Xortx Therapeutics Inc XRTX

$3.0M

Azitra Inc AZTR

$3.8M

GRI Bio GRI

$3.4M

Onconetix ONCO

$1.1M

Frequently Asked Questions

What is Jaguar Health Inc's annual revenue?

Jaguar Health Inc (JAGX) reported $11.7M in total revenue for fiscal year 2024. This represents a 19.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Jaguar Health Inc's revenue growing?

Jaguar Health Inc (JAGX) revenue grew by 19.8% year-over-year, from $9.8M to $11.7M in fiscal year 2024.

Is Jaguar Health Inc profitable?

No, Jaguar Health Inc (JAGX) reported a net income of -$39K in fiscal year 2024, with a net profit margin of -0.3%.

What is Jaguar Health Inc's EBITDA?

Jaguar Health Inc (JAGX) had EBITDA of -$28.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Jaguar Health Inc's gross margin?

Jaguar Health Inc (JAGX) had a gross margin of 83.3% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Jaguar Health Inc's operating margin?

Jaguar Health Inc (JAGX) had an operating margin of -263.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Jaguar Health Inc's net profit margin?

Jaguar Health Inc (JAGX) had a net profit margin of -0.3% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Jaguar Health Inc's return on equity (ROE)?

Jaguar Health Inc (JAGX) has a return on equity of -0.6% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Jaguar Health Inc's free cash flow?

Jaguar Health Inc (JAGX) generated -$29.4M in free cash flow during fiscal year 2024. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Jaguar Health Inc's operating cash flow?

Jaguar Health Inc (JAGX) generated -$29.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Jaguar Health Inc's total assets?

Jaguar Health Inc (JAGX) had $53.4M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Jaguar Health Inc's capital expenditures?

Jaguar Health Inc (JAGX) invested $16K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Jaguar Health Inc spend on research and development?

Jaguar Health Inc (JAGX) invested $16.5M in research and development during fiscal year 2024.

What is Jaguar Health Inc's current ratio?

Jaguar Health Inc (JAGX) had a current ratio of 1.63 as of fiscal year 2024, which is generally considered healthy.

What is Jaguar Health Inc's debt-to-equity ratio?

Jaguar Health Inc (JAGX) had a debt-to-equity ratio of 6.84 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Jaguar Health Inc's return on assets (ROA)?

Jaguar Health Inc (JAGX) had a return on assets of -0.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Jaguar Health Inc's cash runway?

Based on fiscal year 2024 data, Jaguar Health Inc (JAGX) had $8.0M in cash against an annual operating cash burn of $29.4M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Jaguar Health Inc's Piotroski F-Score?

Jaguar Health Inc (JAGX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Jaguar Health Inc's earnings high quality?

Jaguar Health Inc (JAGX) has an earnings quality ratio of 748.64x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Jaguar Health Inc cover its interest payments?

Jaguar Health Inc (JAGX) has an interest coverage ratio of -133.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Jaguar Health Inc?

Jaguar Health Inc (JAGX) scores 17 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.